en · de · es · fr · pt
creatine-notes.peptides6908.com › Data › Compound Identity And Development History — What the Evidence Shows

Compound Identity And Development History — What the Evidence Shows

By Editorial Desk · published 2026-07-28 · last reviewed 2026-08-01 · Data

Albumin conjugation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

Compound Identity and Development History

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

CJC-1295 Structure And Mechanism

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

Cjc-1295 at a glance

PropertyValueNotes
Molecular formulaC152H252N44O42Cited for the form without the drug affinity complex
Molecular weightAbout 3368 DaReported value for modified GRF(1-29)
AppearanceWhite to off-white powderLyophilised solid as usually supplied
SolubilitySoluble in water and polar solventsClarity depends on purity and salt content
Typical storage-20 C or below, dryProtect from light and repeated warming cycles

Background and Naming Conventions

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

Related pages on this site

Albumin Binding and Duration of Action

The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.

Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.

Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.

Reference notes

Organomagnesium compounds are widespread in organic chemistry. They are commonly found as Grignard reagents, formed by reaction of magnesium with haloalkanes or aryl halides in diethyl ether. Examples of Grignard reagents are phenylmagnesium bromide and ethylmagnesium bromide. The Grignard reagents function as a common nucleophile, attacking the electrophilic group such as the carbon atom that is present within the polar bond of a carbonyl group. A prominent organomagnesium reagent beyond Grignard reagents is magnesium anthracene or magnesocene, which is used as a source of highly active magnesium. First prepared in 1954 by independent groups, one led by Ernst Otto Fischer, the other by Albert Wilkinson, magnesocene is a white to off-yellow pyrophoric powder that violently hydrolyses in water. The related butadiene-magnesium adduct serves as a source for the butadiene dianion. Complexes of dimagnesium(I) have been observed.

=== Chemical === Two materials may form a compound at the joint. The strongest joints are where atoms of the two materials share or swap electrons (known respectively as covalent bonding or ionic bonding). A weaker bond is formed if a hydrogen atom in one molecule is attracted to an atom of nitrogen, oxygen, or fluorine in another molecule, a phenomenon called hydrogen bonding. Chemical adhesion occurs when the surface atoms of two separate surfaces form ionic, covalent, or hydrogen bonds. The engineering principle behind chemical adhesion in this sense is fairly straightforward: if surface molecules can bond, then the surfaces will be bonded together by a network of these bonds. It bears mentioning that these attractive ionic and covalent forces are effective over only very small distances – less than a nanometer. This means in general not only that surfaces with the potential for chemical bonding need to be brought very close together, but also that these bonds are fairly brittle, since the surfaces then need to be kept close together.

== Uses == Benzophenone can be used as a photo initiator in ultraviolet (UV)-curing applications such as inks, imaging, and clear coatings in the printing industry. Benzophenone prevents UV light from damaging scents and colors in products such as perfumes and soaps. Benzophenone can also be added to plastic packaging as a UV blocker to prevent photo-degradation of the packaging polymers or its contents. Its use allows manufacturers to package the product in clear glass or plastic (such as a PETE water bottle). Without it, opaque or dark packaging would be required. In biological applications, benzophenones have been used extensively as photophysical probes to identify and map peptide–protein interactions. Benzophenone is used as an additive in flavorings or perfumes for "sweet-woody-geranium-like notes".

Sources: en.wikipedia.org

Notes from published material

== Evolution == Mycorrhizal symbioses are ubiquitous in terrestrial ecosystems, and it is possible that these associations helped to facilitate land colonization by plants. There is paleobiological and molecular evidence that arbuscular mycorrhizas (AM) originated at least 460 million years ago. EcM plants and fungi exhibit a wide taxonomic distribution across all continents (apart from Antarctica), suggesting that the EcM symbiosis has ancient evolutionary roots. Pinaceae is the oldest extant plant family in which symbiosis with EcM fungi occurs, and fossils from this family date back to 156 million years ago. It has been proposed that habitat type and the distinct functions of different mycorrhizas help determine which type of symbiosis is predominant in a given area. In this theory, EcM symbioses evolved in ecosystems such as boreal forests that are relatively productive but in which nutrient cycling is still limiting. Ectomycorrhizas are intermediate in their ability to take up nutrients, being more efficient than arbuscular mycorrhizas and less so than ericoid mycorrhizas, making them useful in an intermediate nutrient situation.

The engineer David Speyrer said this was wrong in hindsight and that Valve could have completed it in two years. Newell felt completing Episode Three just to continue the story would have been a "copout", and said: "The failure, my personal failure, was being stumped. I couldn't figure out why doing Episode Three was pushing anything forward."

=== Development === Thyrotrophs can be identified via immunocytochemistry as early as the 12th week of fetal development, roughly at the same time that gonadotrophs can be detected. The active hormone, TSH, is detected at the 14th week of gestation. Transcription factors, such as Pit-1, GATA-2, and PROP1, influence cell proliferation and maturation.

=== Centrifugal === In centrifugal FFF, the separation field is generated via a centrifugal force. The channel takes the form of a ring, which spins at rotation speeds which can be programmed during the run. The flow and sample are pumped into the channel and centrifuged, allowing the operator to resolve the particles by mass (size and density). The advantage of centrifugal FFF lies in the high size resolution that can be achieved by varying the force applied, since particle size is proportional to particle mass to the third power. The unique advantage presented by centrifugal FFF comes from the techniques capability for high resolution given sufficient buoyant density. This allows for the separation of particles with only a 5% difference in size. Centrifugal FFF has the advantage that particles and macromolecules can be separated by particle density, rather than just particle size. In this instance, two identically sized gold and silver nanoparticles can be separated into two peaks, according to differences in density in the gold and silver nanoparticles, In AF4 separations, the ratio of mass to time is 1:1. With the addition of the third parameter of density to centrifugal FFF, this produces a ratio more akin to mass:time to the power of three. This results in a significantly larger distinction between peaks and result in a greatly improved resolution. This can be particularly useful for novel products, such as composite materials and coated polymers containing nanoparticles, i.e. particles which may not vary in size but which do vary in density.

Sources: en.wikipedia.org

Further detail

== Instrumentation == In DESI, there is a high-velocity pneumatically assisted electrospray jet that is continually directed towards the probe surface. The jet forms a micrometer-size thin solvent film on the sample where it can be desorbed. The sample can be dislodged by the incoming spray jet allowing for particles to come off in an ejection cone of analyte containing secondary ion droplets. A lot of study is still going into looking at the working principals of DESI but there are still some things known. The erosion diameter of the spray spot formed by DESI is known to be directly tied to the spatial resolution. Both the chemical composition and the texture of the surface will also affect the ionization process. The nebulizing gas used most commonly is N2 set at a typical pressure of 160 psi. The solvent is a combination of methanol and water, sometimes paired with 0.5% acetic acid and at a flow rate of 10 μL/min. The surface can be mounted it two different ways, one way consists of a surface holder that can carry 1 x 5 cm large disposable surface slides that lie on a stainless steel surface. The steel surface has a voltage applied to provide an appropriate surface potential. The surface potential that can be applied is the same at which the sprayer can be set at. The second surface is made with an aluminum block that has a built in heater, this allows for temperature control with temperatures up to 300 °C with newer stages having built in CCD's and light sources. Their spectra are that similar to ESI.

== Sites of synthesis == Leptin is produced primarily in the adipocytes of white adipose tissue. It also is produced by brown adipose tissue, placenta (syncytiotrophoblasts), ovaries, skeletal muscle, stomach (the lower part of the fundic glands), mammary epithelial cells, bone marrow, gastric chief cells, and P/D1 cells.

When ε = 0, then R∗ is identically zero: flow is always in the smooth pipe regime. The data for these points lie to the left extreme of the abscissa and are not within the frame of the graph. When R∗ < 5, the data lie on the line B(R∗) = R∗; flow is in the smooth pipe regime. When R∗ > 100, the data asymptotically approach a horizontal line; they are independent of Re, fD, and ⁠ε/D⁠. The intermediate range of 5 < R∗ < 100 constitutes a transition from one behavior to the other. The data depart from the line B(R∗) = R∗ very slowly, reach a maximum near R∗ = 10, then fall to a constant value. Afzal's fit to these data in the transition from smooth pipe flow to rough pipe flow employs an exponential expression in R∗ that ensures proper behavior for 1 < R∗ < 50 (the transition from the smooth pipe regime to the rough pipe regime):

Sources: en.wikipedia.org

Frequently asked questions

What is CJC-1295?

It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.

Is CJC-1295 an approved medicine?

No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.

How does it differ from sermorelin?

Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.

How does CJC-1295 differ from modified GRF(1-29)?

The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.

Network